Song et al. observed that resistant mesenchymal EGFR-mutant lung cancers exhibit an apoptotic defect due to loss of BIM expression, leading to loss of a cell death despite effective suppression of oncogenic signaling by targeted therapy [117]. The gene discussed is BCL2L11; the disease is lung cancer.